# SMAD3

## Overview
SMAD3 is a gene that encodes the SMAD family member 3 protein, a critical intracellular mediator in the transforming growth factor-beta (TGF-β) signaling pathway. The SMAD3 protein functions primarily as a transcription factor, playing a pivotal role in regulating gene expression in response to TGF-β signals. It is characterized by two conserved domains, MH1 and MH2, which are essential for DNA binding and protein interactions, respectively. Upon activation by TGF-β, SMAD3 undergoes phosphorylation, allowing it to form complexes with SMAD4 and translocate to the nucleus to influence transcriptional responses. This protein is involved in various physiological processes, including cell cycle regulation, immune response, and tissue repair, and is implicated in several clinical conditions, such as familial thoracic aortic aneurysm and dissection, Aneurysms-Osteoarthritis Syndrome, and osteoarthritis (Regalado2011Exome; Ten2002Regulation; Attisano2001Thesmads).

## Structure
The SMAD3 protein is characterized by two conserved domains: the MH1 and MH2 domains, separated by a non-conserved linker region. The MH1 domain is involved in DNA binding and forms a compact globular fold, utilizing a conserved 11-residue β hairpin to interact with DNA in the major groove. It also contains a basic helix (H2) with a nuclear localization signal essential for nuclear import (Attisano2001Thesmads). The MH2 domain, which does not bind DNA, is multifunctional and mediates interactions with various proteins. It is composed of five α helices and three loops enclosing a β sandwich, crucial for oligomer formation and interactions with the TGFβ receptor complex (Attisano2001Thesmads).

The MH2 domain of SMAD3 is involved in trimerization, which is essential for its function in TGF-β signaling. This trimerization is induced by phosphorylation, leading to a conformational change that allows SMAD3 to dissociate from the receptor and form a complex with SMAD4 (Qin2002Smad3). The interaction with SARA (Smad Anchor for Receptor Activation) stabilizes certain disordered regions upon binding, inducing a disorder-to-order transition in specific regions (Qin2002Smad3). The linker region between MH1 and MH2 contains motifs for potential phosphorylation by MAPKs, which can regulate SMAD3 activity (Attisano2001Thesmads).

## Function
SMAD3 is a critical component of the TGF-β signaling pathway, functioning primarily as a transcription factor that regulates gene expression in response to TGF-β signals. Upon activation by TGF-β, SMAD3 is phosphorylated by type I receptor kinases, allowing it to form heteromeric complexes with SMAD4. These complexes translocate to the nucleus, where SMAD3 binds to specific DNA sequences or interacts with other transcription factors to regulate target gene transcription (Ten2002Regulation; Feng1998The).

SMAD3 plays a significant role in cell cycle regulation by mediating TGF-β-induced growth arrest. It upregulates cyclin-dependent kinase inhibitors such as p15 INK4b and p21 CIP/WAF1, which inhibit the phosphorylation of the retinoblastoma protein, leading to cell cycle arrest in the G1 phase (Ten2002Regulation). SMAD3 also interacts with transcription factors like Miz-1 and Sp1 to activate the p15 INK4b gene (Ten2002Regulation).

In addition to its role in cell cycle control, SMAD3 is involved in various physiological processes, including immune response, tissue repair, and skeletal health. It regulates the transcription of genes involved in these processes, contributing to cellular homeostasis and organismal health (Ten2002Regulation). SMAD3's interactions with co-activators like p300 and CBP, which have histone acetyltransferase activity, facilitate transcription by modifying chromatin structure (Ten2002Regulation).

## Clinical Significance
Mutations in the SMAD3 gene are associated with several clinical conditions, primarily affecting the cardiovascular and skeletal systems. SMAD3 mutations are a known cause of familial thoracic aortic aneurysm and dissection (FTAAD), accounting for approximately 2% of these cases. These mutations can also lead to intracranial and abdominal aortic aneurysms, as well as bilateral iliac aneurysms (Regalado2011Exome). The gene is implicated in Aneurysms-Osteoarthritis Syndrome (AOS), characterized by arterial aneurysms and early-onset osteoarthritis (Chesneau2020Clinical; Regalado2011Exome).

SMAD3 mutations can result in a range of phenotypes, from minimal features to those resembling Marfan syndrome and Loeys-Dietz syndrome type III. These mutations often disrupt the TGF-β signaling pathway, leading to histological changes in the aorta, such as elastic fiber fragmentation and collagen accumulation (Keravnou2020Identification). In some cases, SMAD3 mutations are linked to melorheostosis, a rare bone disease characterized by abnormal bone growth due to increased TGF-β signaling (Kang2020Somatic).

The gene's involvement in osteoarthritis is also significant, with certain genetic variations in SMAD3 associated with an increased risk of hip and knee osteoarthritis in European populations (Valdes2010Genetic).

## Interactions
SMAD3 is involved in various protein interactions that are crucial for its role in the TGF-β signaling pathway. It interacts with Axin, a known negative regulator in the Wnt signaling pathway, through its C-terminal MH2 domain. This interaction is important for the colocalization of SMAD3 and Axin in the cytoplasm, and Axin facilitates the phosphorylation and activation of SMAD3 by TGF-β receptors (Furuhashi2001Axin). SMAD3 also interacts with Smad4, forming a complex that translocates to the nucleus to regulate gene transcription (Brown2008Identification).

SMAD3 can physically interact with Jun family members, such as JunB, affecting transcriptional responses to TGF-β in a promoter-specific manner. This interaction can either inhibit or enhance transcription depending on the promoter context (Verrecchia2001Smad3AP1). SMAD3 also interacts with the orphan nuclear receptor hepatocyte nuclear factor 4 (HNF-4) through its MH1 domain, which is crucial for the transactivation of specific promoters in hepatic cells (Chou2003Mechanism). These interactions highlight the diverse roles of SMAD3 in modulating cellular responses to TGF-β signaling.


## References


[1. (Chesneau2020Clinical) Bertrand Chesneau, Thomas Edouard, Yves Dulac, Hélène Colineaux, Maud Langeois, Nadine Hanna, Catherine Boileau, Pauline Arnaud, Nicolas Chassaing, Sophie Julia, Guillaume Jondeau, Aurélie Plancke, Philippe Khau Van Kien, and Julie Plaisancié. Clinical and genetic data of 22 new patients with smad3 pathogenic variants and review of the literature. Molecular Genetics &amp; Genomic Medicine, March 2020. URL: http://dx.doi.org/10.1002/mgg3.1132, doi:10.1002/mgg3.1132. This article has 13 citations.](https://doi.org/10.1002/mgg3.1132)

[2. (Chou2003Mechanism) Wan-Chih Chou, Vassiliki Prokova, Keiko Shiraishi, Ulrich Valcourt, Aristidis Moustakas, Margarita Hadzopoulou-Cladaras, Vassilis I. Zannis, and Dimitris Kardassis. Mechanism of a transcriptional cross talk between transforming growth factor-β–regulated smad3 and smad4 proteins and orphan nuclear receptor hepatocyte nuclear factor-4. Molecular Biology of the Cell, 14(3):1279–1294, March 2003. URL: http://dx.doi.org/10.1091/mbc.e02-07-0375, doi:10.1091/mbc.e02-07-0375. This article has 45 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.e02-07-0375)

[3. (Kang2020Somatic) Heeseog Kang, Smita Jha, Aleksandra Ivovic, Nadja Fratzl-Zelman, Zuoming Deng, Apratim Mitra, Wayne A. Cabral, Eric P. Hanson, Eileen Lange, Edward W. Cowen, James Katz, Paul Roschger, Klaus Klaushofer, Ryan K. Dale, Richard M. Siegel, Timothy Bhattacharyya, and Joan C. Marini. Somatic smad3-activating mutations cause melorheostosis by up-regulating the tgf-β/smad pathway. Journal of Experimental Medicine, March 2020. URL: http://dx.doi.org/10.1084/jem.20191499, doi:10.1084/jem.20191499. This article has 28 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1084/jem.20191499)

[4. (Keravnou2020Identification) Anna Keravnou, Evy Bashiardes, Vassilis Barberis, Kyriaki Michailidou, Marinos Soteriou, George A. Tanteles, and Marios A. Cariolou. Identification of novel splice mutation in smad3 in two cypriot families with nonsyndromic thoracic aortic aneurysm. two case reports. Molecular Genetics &amp; Genomic Medicine, June 2020. URL: http://dx.doi.org/10.1002/mgg3.1378, doi:10.1002/mgg3.1378. This article has 4 citations.](https://doi.org/10.1002/mgg3.1378)

[5. (Regalado2011Exome) Ellen S. Regalado, Dong-chuan Guo, Carlos Villamizar, Nili Avidan, Dawna Gilchrist, Barbara McGillivray, Lorne Clarke, Francois Bernier, Regie L. Santos-Cortez, Suzanne M. Leal, Aida M. Bertoli-Avella, Jay Shendure, Mark J. Rieder, Deborah A. Nickerson, and Dianna M. Milewicz. Exome sequencing identifies smad3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circulation Research, 109(6):680–686, September 2011. URL: http://dx.doi.org/10.1161/CIRCRESAHA.111.248161, doi:10.1161/circresaha.111.248161. This article has 326 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1161/CIRCRESAHA.111.248161)

[6. (Furuhashi2001Axin) Masao Furuhashi, Ken Yagi, Hideki Yamamoto, Yoichi Furukawa, Shinji Shimada, Yusuke Nakamura, Akira Kikuchi, Kohei Miyazono, and Mitsuyasu Kato. Axin facilitates smad3 activation in the transforming growth factor β signaling pathway. Molecular and Cellular Biology, 21(15):5132–5141, August 2001. URL: http://dx.doi.org/10.1128/mcb.21.15.5132-5141.2001, doi:10.1128/mcb.21.15.5132-5141.2001. This article has 126 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.21.15.5132-5141.2001)

[7. (Brown2008Identification) Kimberly A. Brown, Amy‐Joan L. Ham, Cara N. Clark, Nahum Meller, Brian K. Law, Anna Chytil, Nikki Cheng, Jennifer A. Pietenpol, and Harold L. Moses. Identification of novel smad2 and smad3 associated proteins in response to tgf‐β1. Journal of Cellular Biochemistry, 105(2):596–611, August 2008. URL: http://dx.doi.org/10.1002/jcb.21860, doi:10.1002/jcb.21860. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.21860)

[8. (Feng1998The) Xin-Hua Feng, Ying Zhang, Rui-Yun Wu, and Rik Derynck. The tumor suppressor smad4/dpc4 and transcriptional adaptor cbp/p300 are coactivators for smad3 in tgf-β-induced transcriptional activation. Genes &amp; Development, 12(14):2153–2163, July 1998. URL: http://dx.doi.org/10.1101/gad.12.14.2153, doi:10.1101/gad.12.14.2153. This article has 422 citations.](https://doi.org/10.1101/gad.12.14.2153)

[9. (Valdes2010Genetic) Ana M. Valdes, Tim D. Spector, Agu Tamm, Kalle Kisand, Sally A. Doherty, Elaine M. Dennison, Massimo Mangino, Ann Tamm, Irina Kerna, Deborah J. Hart, Margaret Wheeler, Cyrus Cooper, Rik J. Lories, Nigel K. Arden, and Michael Doherty. Genetic variation in the smad3 gene is associated with hip and knee osteoarthritis. Arthritis &amp; Rheumatism, 62(8):2347–2352, August 2010. URL: http://dx.doi.org/10.1002/art.27530, doi:10.1002/art.27530. This article has 124 citations.](https://doi.org/10.1002/art.27530)

[10. (Attisano2001Thesmads) Liliana Attisano and Si Tuen Lee-Hoeflich. The smads. Genome Biology, 2(8):reviews3010.1, 2001. URL: http://dx.doi.org/10.1186/gb-2001-2-8-reviews3010, doi:10.1186/gb-2001-2-8-reviews3010. This article has 295 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/gb-2001-2-8-reviews3010)

[11. (Qin2002Smad3) Bin Y. Qin, Suvana S. Lam, John J. Correia, and Kai Lin. Smad3 allostery links tgf-β receptor kinase activation to transcriptional control. Genes &amp; Development, 16(15):1950–1963, August 2002. URL: http://dx.doi.org/10.1101/gad.1002002, doi:10.1101/gad.1002002. This article has 116 citations.](https://doi.org/10.1101/gad.1002002)

[12. (Ten2002Regulation) Peter Ten Dijke, Marie‐José Goumans, Fumiko Itoh, and Susumu Itoh. Regulation of cell proliferation by smad proteins. Journal of Cellular Physiology, 191(1):1–16, February 2002. URL: http://dx.doi.org/10.1002/jcp.10066, doi:10.1002/jcp.10066. This article has 346 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.10066)

[13. (Verrecchia2001Smad3AP1) Franck Verrecchia, Laurence Vindevoghel, Robert J Lechleider, Jouni Uitto, Anita B Roberts, and Alain Mauviel. Smad3/ap-1 interactions control transcriptional responses to tgf-β in a promoter-specific manner. Oncogene, 20(26):3332–3340, June 2001. URL: http://dx.doi.org/10.1038/sj.onc.1204448, doi:10.1038/sj.onc.1204448. This article has 159 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1204448)